Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

European Innovation Council · Ended early

PAREMA PArtial REbreathing for Migraine with Aura

Coordinator
Rehaler AS, Denmark
Runs
1 November 2023 to 31 October 2025
Status
Ended early
EU funding
€1.5m
Total cost
€2.1m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190133087

What the project is doing

In the project's own words, from its summary on CORDIS.

Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life. Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential. The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system.

The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability. To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.

Who is involved

OrganisationCityCountryRole
Rehaler ASAarhus CDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI